Rituximab
- IV / SubcutRituximabMabthera
Mechanism of Action
- A monoclonal antibody that targets CD20, a transmembrane protein on the surface of B cells, resulting in antibody-dependent and complement-dependent cytotoxicity.
Clinical Use
- Indications
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
- Non-Hodgkin lymphoma (NHL)
- Chronic lymphocytic leukaemia (CLL)
- Adverse Effects
- Bone marrow suppression - leucopaenia, anaemia, thrombocytopaenia
- Injection site reactions
- Progressive multifocal leukoencephalopathy (PML)
- Nausea / vomiting
- Angioedema